Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02642653
Recruitment Status : Completed
First Posted : December 30, 2015
Last Update Posted : November 16, 2018
Sponsor:
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
The purpose of the study is to test the efficacy of a 20 week multi-modal treatment comprised of lovastatin or placebo, and the Parent-implemented Language Intervention (PILI) in children with FXS. Children will be randomized to drug or placebo in a double-blind design with all participating in the PILI. The primary endpoint will be to measure improvements in spoken language and behavior among lovastatin-treated than placebo treated participants.

Condition or disease Intervention/treatment Phase
Fragile X Syndrome Genetic Diseases Drug: Lovastatin Other: Placebo Phase 4

Detailed Description:

This is the first multi-modal treatment to combine a targeted treatment for FXS, lovastatin, with an innovative parent-implemented intervention (PILI) targeting language and challenging behavior delivered through telehealth technology.The hypothesis is that targeted treatments will be more effective when applied in combination with PILI. Examination of whether changes in the activity of key pathways/proteins influenced by FMRP (the mitogen-activated protein kinase (ERK) and MMP-9) are biomarkers of treatment responsiveness. Because lovastatin is also an anti-inflammatory, characterization of MEK/ERK signaling in peripheral immune cells both pre- and post- treatment will be carried out to determine whether levels of these signaling molecules are predictive biomarkers of treatment response. It is hypothesized that those individuals with elevated inflammatory cytokine profiles will be most responsive to lovastatin treatment. Once modeled in FXS, results from these studies can then be applied to other neurodevelopmental disorders including Rasopathies.

The behavioral component of the proposed multi-modal treatment will be a Parent-implemented Intervention (PILI) that targets improvements in spoken language and challenging behavior for 10- to 17-year-olds with FXS by increasing parental verbal responsiveness (PVR) within picture-book based story-telling episodes. Parents will be encouraged to use the targeted strategies in other everyday interactions with their child. The intervention will be delivered to parents in their homes by way of video teleconferencing (VTC). Participants will be randomly assigned to receive the behavioral intervention alone or in combination with Lovastatin.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Combining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X Syndrome
Actual Study Start Date : January 2016
Actual Primary Completion Date : July 2018
Actual Study Completion Date : July 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Lovastatin

Arm Intervention/treatment
Active Comparator: Lovastatin and PILI
Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
Drug: Lovastatin
Once per day dosing
Other Name: Mevacor

Placebo Comparator: Placebo and PILI
Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
Other: Placebo
Once per day dosing




Primary Outcome Measures :
  1. Change from baseline in the participant and parent/caregiver Expressive Language Sample composite score in the home [ Time Frame: Baseline, 20 weeks ]
    The expressive language sample is collected from shared interactions around a digital wordless picture book involving the participant with fragile X syndrome and the parent/caregiver in the family home. The composite is created from separate measures of the number of different words used by the participant and the mean length of the communication units measured in morphemes. Samples are collected pre- and post-treatment using different digital books on each occasion, with improvement in the composite expected from pre to post.


Secondary Outcome Measures :
  1. Change from baseline in the participant and mother Expressive Language Sample composite score in the clinic [ Time Frame: Baseline, 20 weeks ]
    The expressive language sample is collected from shared interactions around a wordless picture book involving the participant with fragile X syndrome and the parent/caregiver in the clinic. The composite is created from separate measures of the number of different words used by the participant and the mean length of the communication units measured in morphemes. Samples are collected pre- and post-treatment using different books on each occasion, with improvement in the composite expected from pre to post.

  2. Change from baseline in the FXS- normed Aberrant Behavior Checklist (ABC) social avoidance subscale [ Time Frame: Baseline, 10 weeks, 20 weeks ]
    The ABC-C is a 58- item caregiver-rated behavior scale used to examine treatment effects on challenging behaviors for individuals with FXS in the following domains: (1) irritability, agitation, crying; (2) lethargy, social withdrawal; (3) stereotypic behavior (4) hyperactivity, noncompliance; and (5) inappropriate speech. The social avoidance subscale will be analyzed utilizing the Sansone et al. (2011) FXS-normed ABC scoring measures.

  3. Change from baseline of Symptoms in Fragile X using the Clinical Global Impression-Improvement (CGI-I) scale [ Time Frame: Baseline, 10 weeks, 20 weeks ]
    A clinician rated scale utilizing history from the parents or caregiver and incorporating it into a clinical rating, first for severity, and then for clinical follow-up. The CGI-S will be used at the pre-treatment assessment to judge symptom severity and the CGI- I will be used at the 10 week and 20 week visits.

  4. Change from baseline in the Visual Analog Scale (VAS) [ Time Frame: Baseline, 10 weeks, 20 weeks ]
    The measure will be used to assess parental impressions of progress in two key symptoms: spoken language impairment and social impairment. The distance of the mark from one end is used as the outcome variable for analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documentation of a full mutation with absence or deficient FMRP levels.
  • Males and females ages 10 through 17 years
  • Willingness of potential study participant as well as a parent or caretaker to participate in the protocol.
  • Speech is the primary means of communication with three-word or longer utterances used on a daily basis.
  • IQ ≤70 as measured by the Leiter- R.
  • Sexually active women of childbearing potential (WCBP) must be using a medically acceptable method of birth control and have a negative qualitative serum β-human chorionic growth hormone (β-HCG) or urine pregnancy test collected at the initial screening visit.

Exclusion Criteria:

  • Persons who do not speak English.
  • Changes in any medications (including investigational medications) within the last month (4 weeks). All concomitant medications must have been on a stable course for at least 4 weeks prior to enrollment into the study and maintain stability throughout the course of the study.
  • Changes in behavioral therapy or educational programming during the study. This does not include scheduled school holidays.
  • Have any disease or condition (medical or surgical) at screening that might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product, or would place the subject at increased risk.
  • Patients who, in the opinion of the investigator, are unsuitable in any other way to participate in this study, including being unable to comply with the requirements of the study or displaying clinically significant abnormalities in safety assessments at screening.
  • Patients on prohibited medications
  • History of recurrent status epilepticus.
  • Inability to withhold grapefruit and grapefruit juice from diet during the entire clinical trial.
  • Subjects unwilling to abstain from alcoholic beverages during the trial.
  • Subjects who are actively suicidal.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02642653


Locations
Layout table for location information
United States, California
UC Davis MIND Institute
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
Investigators
Layout table for investigator information
Principal Investigator: Randi J Hagerman, MD UC Davis

Layout table for additonal information
Responsible Party: University of California, Davis
ClinicalTrials.gov Identifier: NCT02642653     History of Changes
Other Study ID Numbers: 520144
First Posted: December 30, 2015    Key Record Dates
Last Update Posted: November 16, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of California, Davis:
Fra(X) Syndrome
Fragile X Syndrome
Fragile X Mental Retardation Syndrome
Mental Retardation, X-linked
Genetic Diseases, X-linked
Trinucleotide Repeat Expansion
Intellectual Disability
Parent Implemented Language Intervention (PILI)
FXS
Neurobehavioral Manifestations
Chromosome Disorders

Additional relevant MeSH terms:
Layout table for MeSH terms
Fragile X Syndrome
Mental Retardation, X-Linked
Genetic Diseases, X-Linked
Syndrome
Genetic Diseases, Inborn
Disease
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Sex Chromosome Disorders
Chromosome Disorders
Congenital Abnormalities
Heredodegenerative Disorders, Nervous System
Lovastatin
L 647318
Dihydromevinolin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors